Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo

Journal of Neuroscience

Volumn 30, Issue 12, 2010, Pages 4190-4196

  Davis, Albert A ^a   Fritz, Jason J ^a   Wess, Jürgen ^b   Lah, James J ^a   Levey, Allan I ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINERGIC RECEPTOR; MUSCARINIC M1 RECEPTOR; ACTIN; ADAM PROTEIN; ADAM10 PROTEIN, MOUSE; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); CARBACHOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; SECRETASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN TISSUE; CONTROLLED STUDY; GENE DELETION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; METABOLITE; MOUSE; NEUROPROTECTION; NONHUMAN; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROCESSING; TRANSGENIC MOUSE; AGE; ANIMAL; ANIMAL EMBRYO; BRAIN CORTEX; CELL CULTURE; CYTOLOGY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; METHODOLOGY; NERVE CELL; PHYSIOLOGY;

ACTINS; ADAM PROTEINS; AGE FACTORS; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CARBACHOL; CELLS, CULTURED; CEREBRAL CORTEX; CHOLINERGIC AGONISTS; EMBRYO, MAMMALIAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; NEURONS; PEPTIDE FRAGMENTS; RECEPTOR, MUSCARINIC M1;

EID: 77949826581     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.6393-09.2010     Document Type: Article

References (34)

1. Alzheimer's Association (2009) 2009 Alzheimer's disease facts and figures. Alzheimers Dement 5:234-270.
2. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6:51-58.
3. Beach TG, Potter PE, Kuo YM, Emmerling MR, Durham RA, Webster SD, Walker DG, Sue LI, Scott S, Layne KJ, Roher AE (2000) Cholinergic deafferentation of the rabbit cortex: a new animal model of Abeta deposition. Neurosci Lett 283:9-12.
4. Beach TG, Kuo YM, Schwab C, Walker DG, Roher AE (2001a) Reduction of cortical amyloid beta levels in guinea pig brain after systemic administration of physostigmine. Neurosci Lett 310:21-24.
5. Beach TG, Walker DG, Potter PE, Sue LI, Fisher A (2001b) Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. Brain Res 905:220-223.
6. Bell KF, Zheng L, Fahrenholz F, Cuello AC (2008) ADAM-10 over-expression increases cortical synaptogenesis. Neurobiol Aging 29:554-565.
7. Buckley NJ, Bonner TI, Brann MR (1988) Localization of a family of muscarinic receptor mRNAs in rat brain. J Neurosci 8:4646-4652.
8. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49:671-682.
9. DeLapp N, Wu S, Belagaje R, Johnstone E, Little S, Shannon H, Bymaster F, Calligaro D, Mitch C, Whitesitt C, Ward J, Sheardown M, Fink-Jensen A, Jeppesen L, Thomsen C, Sauerberg P (1998) Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells. Biochem Biophys Res Commun 244:156-160.
10. Dodson SE, Andersen OM, Karmali V, Fritz JJ, Cheng D, Peng J, Levey AI, Willnow TE, Lah JJ (2008) Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. J Neurosci 28:12877-12886.
11. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO (1989) Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262:2551-2556.
12. Farber SA, Nitsch RM, Schulz JG, Wurtman RJ (1995) Regulated secretion of beta-amyloid precursor protein in rat brain. J Neurosci 15:7442-7451.
13. Gralle M, Botelho MG, Wouters FS (2009) Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. J Biol Chem 284:15016-15025.
14. Haring R, Gurwitz D, Barg J, Pinkas-Kramarski R, Heldman E, Pittel Z, Wengier A, Meshulam H, Marciano D, Karton Y, Fisher A (1994) Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B. Biochem Biophys Res Commun 203:652-658.
15. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60:1119-1122.
16. Hock C, Maddalena A, Raschig A, Müller-Spahn F, Eschweiler G, Hager K, Heuser I,HampelH,Müller-Thomsen T, OertelW,WienrichM,Signorell A, Gonzalez-Agosti C, NitschRM (2003) Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 10:1-6.
17. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28:10422-10433.
18. Kim SH, Kim YK, Jeong SJ, Haass C, Kim YH, Suh YH (1997) Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. Mol Pharmacol 52:430-436.
19. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
20. Lenzken SC, Lanni C, Govoni S, Lucchelli A, Schettini G, Racchi M (2007) Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chem Biol Interact 165:138-145.
21. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR (1991) Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11:3218-3226.
22. Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ (1995) Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci 15: 4077-4092.
23. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE (1993) Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10:243-254.
24. Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A (1998) Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad SciU S A 95:12683-12688.
25. Miyakawa T, Yamada M, Duttaroy A, Wess J (2001) Hyperactivity and intact hippocampus-dependent learning in mice lacking theM1 muscarinic acetylcholine receptor. J Neurosci 21:5239-5250.
26. 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050-4058.
27. Nie H, Li Z, Lukas RJ, Shen Y, Song L, Wang X, YinM (2008) Construction of SH-EP1-alpha4beta2-hAPP695 cell line and effects of nicotinic agonists on beta-amyloid in the cells. Cell Mol Neurobiol 28:103-112.
28. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304-307.
29. Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH (2000) The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 48:913-918.
30. Perry EK, Kilford L, Lees AJ, Burn DJ, PerryRH (2003) Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 54:235-238.
31. Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, Teplow DB, Haass C (1996) The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci 777:57-64.
32. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283:29615-29619.
33. Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, Podlisny MB, Cleary JP, Ashe KH, Rowan MJ, Selkoe DJ (2005) The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 33:1087-1090.
34. Woodruff-Pak DS (2008) Animal models of Alzheimer's disease: therapeutic implications. J Alzheimers Dis 15:507-521.